An analyst unceremoniously chops his recommendation on the stock.
News & Analysis: BioNTech SE
The U.S. government plans to buy hundreds of millions more doses of the company's COVID-19 vaccine to donate to poorer countries.
That spending might help him win the war on cancer.
Many of its bets on gene-based medicine increase the odds of the next blockbuster therapy.
The good far outweighed the bad.
Up 300% since last May, can BioNTech further unlock value for shareholders?
A fascinating new finding put some juice into the biotech's stock.
A Bryan Garnier prognosticator increases her price target despite the recommendation chop.
The German biotech now hopes to leverage its COVID-19 vaccine success to launch new products over the next five years.
Additional capacity may not be as valuable as the initial doses.